Q2 2025 · 13F-HR
EcoR1 Capital, LLCholdings as filed
Filed 2025-08-14 · accession 0000935836-25-000506
$1.69B
Reported value
37
Positions
2025-06-30
Period end
The Brief · EcoR1 Capital, LLC · Q2 2025
AI · grounded in 13F
EcoR1 Capital, LLC established a new position in ZYME valued at $288.3M. The fund also initiated new stakes in APLSUSD for $205.9M and JAZZ for $181.1M. Additional new positions include ANAB at $174.9M and CRNX at $123.3M. Total assets under management stand at $1.69B across 36 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98985Y108 | ZYME | ZYMEWORKS INC | $288.3M | 17.1% | 22,970,388 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $205.9M | 12.2% | 11,895,808 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $181.1M | 10.7% | 1,706,469 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $174.9M | 10.4% | 7,880,094 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $123.3M | 7.30% | 4,288,120 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $106.6M | 6.31% | 10,688,978 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $67.6M | 4.00% | 1,389,276 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $55.6M | 3.29% | 3,988,971 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $54.4M | 3.22% | 10,630,736 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $48.3M | 2.86% | 6,144,767 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $37.9M | 2.25% | 4,079,415 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $34.0M | 2.01% | 1,469,818 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $29.0M | 1.72% | 1,036,945 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $28.9M | 1.71% | 2,030,544 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $24.2M | 1.43% | 4,200,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $23.5M | 1.39% | 440,000 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $22.7M | 1.34% | 75,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $19.0M | 1.13% | 1,271,342 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $18.9M | 1.12% | 200,000 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $18.6M | 1.10% | 935,121 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $16.4M | 0.97% | 1,618,068 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $14.3M | 0.85% | 500,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $14.2M | 0.84% | 500,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $13.1M | 0.78% | 1,149,794 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $12.2M | 0.72% | 3,917,546 | Common | SOLE |
| 695127100 | PCRX | PACIRA BIOSCIENCES INC | $10.9M | 0.65% | 457,471 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $7.9M | 0.47% | 850,341 | Common | SOLE |
| 59267L107 | — | METSERA INC | $7.7M | 0.46% | 271,529 | Common | SOLE |
| 00653A107 | ADAPY | ADAPTIMMUNE THERAPEUTICS PLC | $6.6M | 0.39% | 27,404,070 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $5.6M | 0.33% | 862,068 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $4.8M | 0.29% | 2,420,243 | Common | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $4.4M | 0.26% | 573,183 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.0M | 0.12% | 1,091,417 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $1.9M | 0.11% | 1,602,717 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $1.9M | 0.11% | 135,000 | CALL | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $1.9M | 0.11% | 963,333 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $595,985 | 0.04% | 66,665 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.